Much of the clinical data on drugs and medical devices comes from studies conducted on very homogeneous cohorts of patients. This improves the significance of the result on that type of patient, but introduces a modest degree of uncertainty for those types of patients who deviate from the characteristics of the groups enrolled in the clinical study.
The continuous dialogue between Diadema Farmaceutici with the medical professionals can improve analysis on:
- effectiveness,
- tolerability,
- therapeutic adherence
- care experience
of its products, in order to understand in deep what happens in the most different conditions and always have updated information on its product portfolio.